MEETINGS - Workshop on Central-East European Countries and European Community: IVD (in vitro diagnostic) Directive 98/79/EC and Central-East European Countries Regulations (Czech Republic) September 2002:
This article was originally published in Clinica
The European Diagnostics Manufacturers Association (EDMA) is hosting a workshop on Central-East European Countries and European Community: IVD Directive 98/79/EC and Central-East European Countries Regulations on September 24 2002 at the Hotel Pyramida, Prague, Czech Republic. Workshop highlights include the EDMA Central Europe Working Party and its activities, details on Switzerland adopting the CE mark, industry and competent authority perspectives of the IVD Directive, and CEEC regulations and future prospects. Further details from EDMA, on tel: +32 2772 2225; fax: +32 2772 2329; email: email@example.com www.edma.ivd.be
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.